44 results about "Therapy alcoholism" patented technology

The present invention provides for the use of combinations of drugs to treat addictive disorders. More specifically, the present invention provides compositions and methods for treating disorders using combinations of drugs such as topiramate, ondansetron, and naltrexone.

The present invention features compositions for intranasal administration comprising an opioid receptor antagonist. The invention also features methods of using such compositions in the treatment of various diseases and disorders, such as the treatment of alcoholism. In certain embodiments, the opioid receptor antagonist is naltrexone or a pharmaceutically acceptable salt thereof.

The present invention provides compositions, methods, and kits for administration of nalmefene for treatment of alcoholism, nicotine dependence, or another condition for which treatment with nalmefene is therapeutically beneficial. The invention provides a biocompatible nonerodible polymeric device which releases nalmefene continuously with generally linear release kinetics for extended periods of time. Nalmefene is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with nalmefene.

Compositions and methods for treating, preventing, or reducing alcoholism, in particular methods for increasing patient compliance with therapies that require the intake of an ALDH inhibitor comprising the step of administering a monoamine oxidase B inhibitor.

The present invention relates to a method of treating alcoholism or alcohol abuse by administering to a subject a pharmaceutically effective amount of an opioid antagonist before imminent drinking. Particularly, the present invention relates to a method of treating alcoholism or alcohol abuse by administering transmucosally to a subject a pharmaceutically effective amount of an opioid antagonist before imminent drinking. Preferably, the opioid antagonist used in the method is nalmefene or a pharmaceutically acceptable salt thereof. The invention also relates to a method of treating alcoholism or alcohol abuse by administering to a subject before imminent drinking a transmucosal preparation comprising a pharmaceutically effective amount of an opioid antagonist, wherein the transmucosal preparation has rapid onset of action. Advantageously, a FAH+ subject is treated. Further, the invention relates to a method of treating alcoholism or alcohol abuse of a FAH+ subject, comprising extinguishing an alcohol-drinking response by administering to the FAH+ subject a pharmaceutically effective amount of nalmefene or a pharmaceutically acceptable salt thereof.

The present invention provides for compositions and methods for treating or preventing addictive and compulsive diseases and disorders, particular alcohol-related diseases and disorders, disclosed herein. The GLP activators of the present invention are effective against various alcohol and drug dependency diseases. In accordance with the invention, the present compositions and methods can be used to intercede upstream or downstream in the signal transduction cascade involved in GLP action to treat various alcohol and drug dependency diseases. In one embodiment, the synthesis or release of endogenous GLP can be stimulated. In another embodiment, the endogenous synthesis or release of another molecule active in the cascade downstream from GLP, (e.g., a molecule produced in response to GLP binding to a receptor), can be stimulated. Accordingly, the methods and compositions of the invention are useful for preventing, treating, diagnosing, or monitoring the progression various alcohol and drug dependency diseases disclosed herein.

Compositions and methods for treating, preventing, or reducing alcoholism, in particular methods for increasing patient compliance with therapies that require the intake of an ALDH inhibitor comprising the step of administering a monoamine oxidase B inhibitor.

Alcoholism, and symptoms and negative effects thereof may be treated using ibudilast or a pharmaceutically acceptable salt thereof. Abstinence from alcohol consumption may be maintained using ibudilast or a pharmaceutically acceptable salt thereof. Withdrawal from alcohol may be facilitated and negative effects thereof reduced by using ibudilast or a pharmaceutically acceptable salt thereof.

The present invention relates to a medicine for curing alcoholism-metadoxine freeze-dried powder injection and its preparation process. The proper quantity of anti-oxidant and chelator can be added in its medicine preparation formula composition so as to raise the stability of said medicinal component. The pharmacodynamic tests show that it has remittence action for rat liver injury due to carbontetrachloride. Said injection is stable, and is favorable for storage and transportation.

The invention provides transdermal patches comprising an adhesive and a composition comprising naltrexone and either methyl oleate or isopropyl myristate, a kit comprising a plurality of such transdermal patches, a composition comprising naltrexone and methyl oleate, such a composition for use as a medicament, and compositions comprising naltrexone and methyl oleate or isopropyl myristate for use in the treatment of alcoholism or opiate addiction.

The present invention provides an implantable composition which contains disulfiram, an anti-inflammatory agent, and optionally a pharmaceutically acceptable carrier. Methods of making the implants, and methods of using the implants to treat alcoholism and opioid dependency are also disclosed.

In the treatment of alcoholism, co-treatment with an active agent capable of offsetting unwanted adverse clinical manifestations to the treatment itself, for example, negative drug adverse clinical manifestations, greatly increases patient compliance. Increasing patient compliance, in turn, creates a better success rate and decreased recidivism or relapse. The current invention combines the use of an opioid antagonist with at least one dopamine D2 partial agonist for the treatment of alcoholism. Suitable dopamine D2 partial agonists are aripiprazole and (−)3-(3-hydroxyphenyl)-N-n-propylpiperidine [(−)-3PPP].

The invention discloses a Chinese herbal compound preparation used for treating alcoholism and gout, mainly comprising the following components in parts by weight: 10-40 parts of kudzuvine root, 15-40 parts of hovenia acerba, 3-10 parts of pseudo-ginseng, 3-15 parts of phyllanthus emblica, 3-10 parts of fructus amomi, 35-10 parts of myristica fragrans, 3-15 parts of dchisandra chinensis, 4-15 parts of American olive, 10-20 parts of honeysuckle, 10-30 parts of rhizoma smilacis glabrae, 10-30 parts of coix seed, 10-30 parts of poria cocos, 10-20 parts of zaocys dhumnade, 10-20 parts of lucid ganoderma, 10-20 parts of American ginseng and 10-20 parts of turmeric. No hepatorenal dysfunction is caused when the compound preparation disclosed by the invention is used for treating hyperuricosuria, which shows that the preparation has no obvious toxic or side effect and mild medicine property, thus the preparation is beneficial to long-term administration. The inventor also knows that medicine taking compliance of patients and tolerance are good from some follow-up visited patients, annual attack frequency is reduced, and the preparation disclosed by the invention has obvious treatment effect on combined diabetes mellitus, hyperlipidemia and vascular hypertension, thus the preparation disclosed by the invention can be regarded as a safe Chinese herbal compound preparation which can be taken by a patient who is repeatedly attacked by acute gouty arthritis for a long time and can control symptoms and reduce attack frequency.

The invention discloses an alcohol-dissolving liver-protecting healthy food, which comprises the following raw materials (by weight portion), hedgehog fungus 35-45 parts, kudzuvine root 25-35 parts, oyster 16-24 parts, licorice root 8-12 parts, white peony root 8-12 parts, nutgrass flatsedge rhizome 8-12 parts. The food can be prepared into capsules, tablets, pills, electuary or other dosage forms.

This application relates to a method for treating various aspects of alcoholism, including alcohol craving and relapse into alcoholism, by the administration of an effective amount of gaseous anaesthesia to a deep surgical anaesthesia. The method can be applied for the alleviation of addiction and craving associated with amphetamine use, and for the alleviation of psychosis in schizophrenia and the alleviation of psychosis in Alzheimer's disease. In addition, the state of addiction or the state of psychosis, or the state of alcohol withdrawal can be monitored in animal tissue in vitro or in humans in vivo by measuring the density of the high-affinity states of the dopamine D2 receptors in the striatum or other brains regions containing these receptors which are elevated in these conditions.

The present invention relates to the use of a substance that inhibits the Y2 receptor of neuropeptide Y for the preparation of a pharmaceutical composition for treatment of alcoholism. It also relates to a pharmaceutical composition comprising at least one substance with activity against alcohol consumption.

The invention discloses an alcohol-dissolving liver-protecting healthy food, which comprises the following raw materials (by weight portion), hedgehog fungus 35-45 parts, kudzuvine root 25-35 parts, oyster 16-24 parts, licorice root 8-12 parts, white peony root 8-12 parts, nutgrass flatsedge rhizome 8-12 parts. The food can be prepared into capsules, tablets, pills, electuary or other dosage forms.

The invention discloses a pharmaceutical composition for treating alcoholism and protecting liver. The pharmaceutical composition is characterized by being prepared from, by weight, 0.5-1.5 parts of vitamin B1, 0.1-1 part of vitamin B2, 2-4 parts of nicotinamide, 0.1-0.5 part of dextro-calcium pantothenate, 0.1-0.5 part of vitamin B6 and 95-100 parts of folium callicarpae nudiflorae. The pharmaceutical composition, which is in the form of an oral preparation, is simple in preparation process and convenient to carry; the pharmaceutical composition, in a mode of combining traditional Chinese medicines and western medicines, aims at promoting alcohol metabolism by protecting the liver, promoting activity of hepatic cell active enzyme and regulating metabolic balance of the liver, so that an effect of dispelling alcohol effects is achieved.

The invention provides a pharmaceutical composition for preventing or treating alcoholic poisoning and alcoholic liver damage and a preparation method thereof. The traditional Chinese medicine is prepared from raw materials of haw, Chinese yam, soya lecithin, and fructo-oligosaccharide. The pharmaceutical composition has the characteristics of definite therapeutic effect, little side effect, simple preparation method, and low cost, and provides a new choice for clinical application.

This disclosure relates to oligonucleotides, compositions and methods useful for reducing ALDH2 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of ALDH2 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of ALDH2 expression may also include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat alcoholism and related conditions.

The invention discloses a technical scheme of application of a raphanin or a plant extract with the raphanin in preparing a functional food or medicine for preventing and treating alcoholic psychosis.Researches show that the raphanin is capable of enhancing the expression of catalase in a body by activating Nrf2 transcription activity, so that a powerful capability that ethanol is converted intoacetaldehyde is resulted in a brain, and the inhibition effect of the ethanol upon the brain can be alleviated. Therefore, the raphanin can be adopted to prepare medicines and functional foods for preventing or treating alcoholism. The raphanin can be a chemical monomer, or the plant extract with the raphanin can be also used.

Disclosed are pharmaceutical compositions comprising a benzodiazepine, an alcohol aversive agent, and an abuse aversive agent, and methods of use in preventing alcohol or cocaine abuse.

The invention provides an anti-alcohol composition. The anti-alcohol composition comprises, by weight, 5-15 parts of Radix Puerariae, 5-15 parts of Flos Puerariae. 5-15 parts of Radix Sophorae Flavescentis, 3-10 parts of Myristica Fragrans, 8-20 parts of Fructus Gardeniae, 2-5 parts of tangerine peel and 2-5 parts of ginger. The method includes the following steps: crushing components in the anti-alcohol composition prior to mixing; (2) adding water to decoct the anti-alcohol composition for 1-2h; 3) filtering and collecting decoction, adding water into filtered dregs, and then decocting for 0.5-1h; (4) repeating the step (3) for 2-4 times prior to collecting decoction; (5) concentrating decoction to obtain oral liquid. The invention further provides application of the anti-alcohol composition in preparation of drugs for treating alcoholism.